Trial Profile
A Single-Arm Study Assessing the Safety and Efficacy of Paclitaxel-Eluting Nitinol Stents (Zilver PTX) in the Treatment of Superficial Femoral Artery (SFA) lesions at 12 and 24 Months
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral arterial occlusive disorders; Peripheral artery restenosis
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2017 New trial record